Iyer, S, Trümper, L, O’Connor, O A, Pro, B, Illidge, T, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T, Menne, T, Belada, D, Illès, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A, Hüttmann, A, Savage, K J, Yuen, S, Zinzani, P L, Miao, H, Bunn, V, Fenton, K, Fanale, M, Puhlmann, M & Horwitz, S 2021, ' Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma ', Clinical Lymphoma Myeloma and Leukemia, vol. 21, no. Suppl. 1, pp. S203 . https://doi.org/10.1016/S2152-2650(21)01276-3
Horwitz, S M, O'Connor, O A, Pro, B, Illidge, T, Iyer, S P, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T A, Menne, T, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A R, Hüttmann, A, Savage, K J, Yuen, S, Zinzani, P-L, Miao, H, Bunn, V, Fenton, K, Fanale, M A, Puhlmann, M & Truemper, L 2020, ' The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma ', Blood, vol. 136, no. Suppl. 1, pp. 3-5 . https://doi.org/10.1182/blood-2020-134398
Biccler, J L, El-Galaly, T C, Bøgsted, M, Jørgensen, J, de Nully Brown, P, Poulsen, C B, Starklint, J, Juul, M B, Christensen, J H, Josefsson, P, Dessau, A & Jakobsen, L H 2019, ' Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas ', Leukemia and Lymphoma, vol. 60, no. 6, pp. 1580–1583 . https://doi.org/10.1080/10428194.2018.1540044 Biccler, J L, El-Galaly, T C, Bøgsted, M, Jørgensen, J, de Nully Brown, P, Poulsen, C B, Starklint, J, Juul, M B, Christensen, J H, Josefsson, P, Dessau, A & Jakobsen, L H 2019, ' Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas ', Leukemia and Lymphoma, vol. 60, no. 6, pp. 1580-1583 . https://doi.org/10.1080/10428194.2018.1540044
Jakobsen, L H, Ellin, F, Smeland, K B, Wästerlid, T, Christensen, J H, Jørgensen, J M, Josefsson, P L, Øvlisen, A K, Holte, H, Blaker, Y N, Grauslund, J H, Bjørn, J, Molin, D, Lagerlöf, I, Smedby, K E, Colvin, K, Thanarajasingam, G, Maurer, M J, Habermann, T M, Song, K W, Zhu, K Y, Gerrie, A S, Cheah, C Y & El-Galaly, T C 2020, ' Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients ', British Journal of Haematology. Supplement, vol. 189, no. 4, pp. 661-671 . https://doi.org/10.1111/bjh.16425 Jakobsen, L H, Ellin, F, Smeland, K B, Wästerlid, T, Christensen, J H, Jørgensen, J M, Josefsson, P L, Øvlisen, A K, Holte, H, Blaker, Y N, Grauslund, J H, Bjørn, J, Molin, D, Lagerlöf, I, Smedby, K E, Colvin, K, Thanarajasingam, G, Maurer, M J, Habermann, T M, Song, K W, Zhu, K Y, Gerrie, A S, Cheah, C Y & El-Galaly, T C 2020, ' Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients ', British Journal of Haematology, vol. 189, no. 4, pp. 661-671 . https://doi.org/10.1111/bjh.16425
Kater, A P, Christensen, J H, Bentzen, H H, Niemann, C U, Hutchings, M, Chen, J, Rios, M, Palenski, T, Li, T & Mato, A R 2021, ' Subcutaneous Epcoritamab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Preliminary Results from the Epcore CLL-1 Trial ', Blood, vol. 138, no. Supplement 1, 2627 . https://doi.org/10.1182/blood-2021-146563
Mehta, A, Trneny, M, Ribrag, V, Dartigeas, C, Christensen, J H, Pane, F, Rodríguez, G, Taszner, M, Venugopal, P, Zilioli, V R, Zheng, F, DeMarini, D J, Jiang, W & Zinzani, P L 2021, ' Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor: Primary Analysis from a Phase 2 Study (CITADEL-205) ', Blood, vol. 13, no. Suppl. 1, 382 . https://doi.org/10.1182/blood-2021-147867
Iyer, S, Trumper, L, O'Connor, O A, Pro, B, Illidge, T, Advani, R, Bartlett, N L, Christensen, J H, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, W S, Feldman, T A, Menne, T, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S-P, Shustov, A R, Hüttmann, A, Savage, K J, Yuen, S, Zinzani, P L, Miao, H, Bunn, V, Fenton, K, Fanale, M, Puhlmann, M & Horwitz, S M 2021, ' TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma ', Clinical Lymphoma, Myeloma & Leukemia, vol. 21, no. Suppl. 1, S247 . https://doi.org/10.1016/S2152-2650(21)01557-3